CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — Investor Presentation (November 2010)

8 slides from CTi Biopharma's investor presentation, Nov 17, 2010

  1. Slide 1: CTI Corporate Presentation November 2010

    Exhibit 99.1 CTI Corporate Presentation November 2010 James A. Bianco, M.D. Chief Executive Officer

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and oper

  3. Slide 3: Investment considerations

    Investment considerations Attractive late-stage product portfolio • Potential approval and EU launch in 2011 Products targeting large market opportunities • Lymphoma – 25,000 patients/yr • Ovarian Cancer- 30,000 patients/yr • Breast Cancer – 100,000 patients/yr History of important & meaningful adva

  4. Slide 4: Development Update: Advancing Portfolio Toward Market

    Development Update Advancing Portfolio Toward Market • Pixuvri™ - EMA acceptance of Marketing Authorization Application • Potential approval in Q4-2011 - Appealing FDA decision on New Drug Application • Decision expected within 30 days from submission - Preparing initiation of PIX306 Phase III trial

  5. Slide 5: Corporate Update: Roll-up Strategy - Successful acquisition strategy

    Corporate Update: Roll-up Strategy Successful acquisition strategy • Two product approvals - Trisenox® - acquired 2000 • NDA and launch 2000 • MAA and launch 2001 • Peak sales $22mm - sold to Cephalon $70mm - Zevalin® - • sBLA 2007 • Sales $11mm -sold to Spectrum $31.5mm 5

  6. Slide 6: Corporate Update: Roll-up Strategy

    Corporate Update: Roll-up Strategy Excellent track record uncovering viable products • Aloxi – 2008 WW sales $400mm - Helsin offered opportunity for Phase III program to CTI • $30mm upfront, $65mm success fees • Couldn’t support acquisition internally – MGI pharma acquired rights • Eisai acquired MG

  7. Slide 7: Corporate Update: Roll-up Strategy

    Corporate Update: Roll-up Strategy Rationale • Many attractive undervalued and under-resourced late-stage assets or technology platforms • Several large institutional funds preliminarily interested in putting money to work behind CTI’s proven acquisition track record In preliminary discussions with

  8. Slide 8: Corporate Update: Summary

    Corporate Update: Summary Continued progress advancing existing pipeline products toward commercialization Upcoming potential key milestones expected over next 12 months • FDA decision expected on appeal • PIX 306 initiation • Targeting execution of 1 or more acquisition candidates • Expected interi

Cell Therapeutics — Investor Presentation (November 2010) on 6ix